|
|
|
 > Review 2013 > TCTAP Daily Newspaper |
 |
|
|
 April 25 (Thu.), 2013 |
| Late Breaking Clinical Trials |
Highlights
from the "Late Breaking Clinical Trials" meeting will be held
9:30 AM - 10:25 AM at the Main Arena, Level 3. Brand new data from this
year will be presented for the first time. These sessions provide notable
exposure and recognition for studies likely to significantly affect clinical
practice. Evaluation of the presentation in the Late Breaking Clinical Trial
sessions will be based on the impact and novelty of the research. Late Breaking
Clinical Trials at TCTAP 2013 covers information on the latest scientific
breakthroughs on five featured topics including drug-eluting stents, acute
coronary syndrome, diabetes mellitus, transcatheter aortic valve implantation,
and functional angioplasty.
- Comparison of Platinum Chromium Versus Cobalt Chromium........
|
| 2013 TCTAP Wrap-up Interview |
 Fractional
flow reserve (FFR) is a reliable functional index for epicardial coronary
stenosis. It has been previously reported that deferring lesions of intermediate
severity
at angiography with a FFR 0.75-0.80 has a good clinical follow-up. Especially
in multivessel disease, FFR-guided PCI led to better clinical outcome compared
with angioguided PCI. Evidences support that physiologic assessment is essential
to make a
decision on how to treat. Recent studies validated the optimal MLA threshold
predicting
FFR. Although the MLA cut-offs are ranged from 2.0-3.0 mm, they suggested
that there is no MLA cut-off showing accuracy higher than 70%. Even in subgroupspecific
MLA cut-off (according to vessel size, lesion segment, LAD or non-LAD),
their predictabilities were disappointing.
Because MLA is only one of the multiple determinants of FFR, it cannot predict
FFR accurately. Thus, the decision for treatment should be based on the
functional lesion assessment. With regard to stent optimization, IVUS criteria
have been well established and.......
|
| Acute Coronary Syndrome: Evolving Issues |
 Acute
Chest Pain in the Emergency Room
Acute myocardial infarction (AMI) represents the most urgent
form of acute coronary
syndrome and requires immediate diagnosis and treatment for improved outcomes.
For patients presenting with STsegment elevation MI (STEMI), the diagnosis
is rather apparent from the combination of clinical symptoms and EKG changes.
However, for
those with non- STEMI, the diagnosis may not be simple, especially when
the EKG is not
diagnostic and /or the symptoms are atypical.
For these patients, it is paramount to make the correct diagnosis with
the aid of cardiac biomarkers. Novel hs-troponin could facilitate the
prompt and correct diagnosis of non-STEMI and prevent unwarranted discharge
or delay of treatment for patients at high risk for ischemic complications.
An advantage of hs-troponin includes the ability to detect extremely minute
amounts of cardiac troponin levels and thus, enables both early diagnosis
of myocardial injury and identification of small myocardial infarction.
Recent studies........
|
|
|
|
|
|
|
|
|
